GSA Capital Partners LLP Sells 78,250 Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)

GSA Capital Partners LLP lowered its holdings in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) by 21.5% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 285,588 shares of the biotechnology company’s stock after selling 78,250 shares during the quarter. GSA Capital Partners LLP owned about 0.14% of BioCryst Pharmaceuticals worth $2,170,000 as of its most recent filing with the SEC.

Other large investors also recently made changes to their positions in the company. ProShare Advisors LLC grew its holdings in BioCryst Pharmaceuticals by 9.1% during the 1st quarter. ProShare Advisors LLC now owns 48,503 shares of the biotechnology company’s stock worth $246,000 after acquiring an additional 4,041 shares during the last quarter. XTX Topco Ltd lifted its position in shares of BioCryst Pharmaceuticals by 299.0% during the second quarter. XTX Topco Ltd now owns 156,946 shares of the biotechnology company’s stock worth $970,000 after purchasing an additional 117,607 shares in the last quarter. Seven Eight Capital LP grew its stake in shares of BioCryst Pharmaceuticals by 1,407.1% during the second quarter. Seven Eight Capital LP now owns 169,612 shares of the biotechnology company’s stock valued at $1,048,000 after purchasing an additional 158,358 shares during the last quarter. Susquehanna Fundamental Investments LLC acquired a new stake in shares of BioCryst Pharmaceuticals in the first quarter valued at approximately $327,000. Finally, Rice Hall James & Associates LLC raised its position in BioCryst Pharmaceuticals by 4.0% in the 3rd quarter. Rice Hall James & Associates LLC now owns 2,163,743 shares of the biotechnology company’s stock worth $16,444,000 after purchasing an additional 84,102 shares during the last quarter. Institutional investors own 85.88% of the company’s stock.

BioCryst Pharmaceuticals Price Performance

BioCryst Pharmaceuticals stock opened at $8.19 on Tuesday. BioCryst Pharmaceuticals, Inc. has a fifty-two week low of $4.03 and a fifty-two week high of $8.88. The firm has a market capitalization of $1.70 billion, a price-to-earnings ratio of -13.43 and a beta of 1.89. The company’s 50 day simple moving average is $7.75 and its 200 day simple moving average is $7.07.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last announced its quarterly earnings results on Monday, November 4th. The biotechnology company reported ($0.07) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.07). The firm had revenue of $117.10 million during the quarter, compared to analyst estimates of $113.99 million. BioCryst Pharmaceuticals’s quarterly revenue was up 35.1% on a year-over-year basis. During the same period last year, the firm earned ($0.19) EPS. As a group, analysts predict that BioCryst Pharmaceuticals, Inc. will post -0.38 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several research firms have recently commented on BCRX. JMP Securities lifted their target price on BioCryst Pharmaceuticals from $15.00 to $16.00 and gave the company a “market outperform” rating in a research note on Tuesday, August 6th. HC Wainwright reiterated a “buy” rating and issued a $30.00 price objective on shares of BioCryst Pharmaceuticals in a research report on Tuesday, August 6th. Needham & Company LLC restated a “buy” rating and set a $14.00 target price on shares of BioCryst Pharmaceuticals in a research report on Tuesday, November 5th. StockNews.com upgraded shares of BioCryst Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Tuesday, August 6th. Finally, Barclays boosted their price target on shares of BioCryst Pharmaceuticals from $7.00 to $8.00 and gave the stock an “equal weight” rating in a research note on Tuesday, November 5th. One equities research analyst has rated the stock with a hold rating and six have given a buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $14.67.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.